Advances in emerging drugs for osteosarcoma

Expert Opinion on Emerging Drugs

Volumn 20, Issue 3, 2015, Pages 495-514

  Hattinger, Claudia Maria ^a   Fanelli, Marilù ^a   Tavanti, Elisa ^a   Vella, Serena ^a   Ferrari, Stefano ^a   Picci, Piero ^a   Serra, Massimo ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

drug resistance; osteosarcoma; pharmacogenetics; pharmacogenomics; tailored therapy; targeted drugs

Indexed keywords

ALISERTIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CISPLATIN; CIXUTUMUMAB; CURCUMIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; ERIBULIN; EVEROLIMUS; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; IRINOTECAN SUCROSOFATE; METHOTREXATE; MIFAMURTIDE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PAZOPANIB; POLO LIKE KINASE 1; PROGRAMMED DEATH 1 LIGAND 1; RAPAMYCIN; RECOMBINANT ENDOSTATIN; SONIDEGIB; SORAFENIB; THIOTEPA; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CLINICAL EVALUATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HUMAN; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; NONHUMAN; OSTEOSARCOMA; STEM CELL TRANSPLANTATION; ANIMAL; BONE NEOPLASMS; DRUG DESIGN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT SELECTION; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DRUG DESIGN; HUMANS; OSTEOSARCOMA; PATIENT SELECTION; PROGNOSIS;

EID: 84940390988     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.1051965     Document Type: Article

References (130)

1. Picci P. Classic osteosarcoma. In: Picci P, Manfrini M, Fabbri N, Gambarotti M, Vanel D, editors. Atlas of musculoskeletal tumors and tumorlike lesions. Springer International Publishing Switzerland; Cham: 2014. p. 147-52
2. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997; 33(11): 1725-31
3. Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study. Lancet Oncol 2014; 15(1): 35-47
4. Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 2011; 47(16): 2431-45
5. Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. Curr Opin Pharmacol 2014; 16: 15-23
6. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007; 19(4): 341-6
7. Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther 2013; 137(1): 89-99
8. Hattinger CM, Pasello M, Ferrari S, et al. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 2010; 15(4): 615-34
9. Heymann D, Redini F. Targeted therapies for bone sarcomas. Bonekey Rep 2013; 2: 378
10. Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcomes for osteosarcoma: An international collaboration. Eur J Cancer 2009; 45(13): 2367-75
11. Ferrari S, Briccoli A, Mercuri M, et al. Late relapse in osteosarcoma. J Pediatr Hematol Oncol 2006; 28(7): 418-22
12. Bacci G, Briccoli A, Longhi A, et al. Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 2005; 44(7): 748-55
13. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival. J Clin Oncol 2003; 21(4): 710-15
14. Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 2011; 47(6): 895-902
15. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 2006; 32(6): 423-36
16. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23(3): 559-68
17. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152: 3-13
18. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer 2014; 14(11): 722-35
19. Poos K, Smida J, Maugg D, et al. Genomic heterogeneity of osteosarcoma-shift from single candidates to functional modules. PLoS ONE 2015; 10(4): e0123082
20. Smida J, Baumhoer D, Rosemann M, et al. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res 2010; 16(16): 4256-67
21. Wang LL. Biology of osteogenic sarcoma. Cancer J 2005; 11(4): 294-305
22. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006; 6(7): 1075-85
23. He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett 2014; 7(5): 1352-62
24. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3): iii113-23 doi: 10. 1093/annonc/mdu256
25. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: An updated report. J Clin Oncol 2000; 18(24): 4016-27
26. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003; 25(11): 845-53
27. Bacci G, Mercuri M, Longhi A, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with nonmetastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005; 41(14): 2079-85
28. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99(2): 112-28
29. McTiernan A, Jinks RC, Sydes MR, et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup. Eur J Cancer 2012; 48(5): 703-12
30. Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: The EURAMOS experience. Cancer Treat Res 2009; 152: 339-53
31. Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatmentdagger. Ann Oncol 2015; 26(2): 407-14
32. Bielack S, Kempf-Bielack B, Von Kalle T, et al. Controversies in childhood osteosarcoma. Minerva Pediatr 2013; 65(2): 125-48
33. Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: Treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 2000; 7(2): 339-46
34. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21(10): 2011-18
35. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11(3): 449-53
36. Ferguson WS, Harris MB, Goorin AM, et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol 2001; 23(6): 340-8
37. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study. J Clin Oncol 1998; 16(11): 3641-8
38. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 2001; 19(1): 171-82
39. Seibel NL, Krailo M, Chen Z, et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. Cancer 2007; 109(8): 1646-53
40. Qi WX, He AN, Tang LN, et al. Efficacy and safety of gemcitabinedocetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: A retrospective study of 18 patients. Jpn J Clin Oncol 2012; 42(5): 427-31
41. Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer 2012; 59(5): 854-8
42. Song BS, Seo J, Kim DH, et al. Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience. Pediatr Blood Cancer 2014; 61(8): 1376-81
43. Meyers PA, Chou AJ. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Adv Exp Med Biol 2014; 804: 307-21
44. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009; 27(4): 557-65
45. Sajadi KR, Heck RK, Neel MD, et al. The incidence and prognosis of osteosarcoma skip metastases. Clin Orthop Relat Res 2004(426): 92-6
46. Berger M, Grignani G, Ferrari S, et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 2009; 115(13): 2980-7
47. Briccoli A, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities metastatic to the lung: longterm results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol 2010; 19(4): 193-9
48. Casali PG, Bruzzi P, Bogaerts J, Blay JY. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper. Ann Oncol 2015; 26(2): 300-6
49. Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep 2014; 7(1): 104-12
50. Kuijjer ML, Hogendoorn PC, Cleton-Jansen AM. Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor. Int J Cancer 2013; 133(11): 2512-21
51. Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA 2014; 111(51): E5564-73
52. Mirabello L, Yu K, Berndt SI, et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer 2011; 11: 209
53. Musselman JR, Bergemann TL, Ross JA, et al. Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: A Children's Oncology Group (COG) study. Int J Mol Epidemiol Genet 2012; 3(4): 286-93
54. Windsor RE, Strauss SJ, Kallis C, et al. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: A pilot study. Cancer 2012; 118(7): 1856-67
55. Savage SA, Mirabello L, Wang Z, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet 2013; 45(7): 799-803
56. Egas-Bejar D, Anderson PM, Agarwal R, et al. Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: The human fingerprint hypothesis. Oncoscience 2014; 1(2): 167-79
57. Forscher C, Mita M, Figlin R. Targeted therapy for sarcomas. Biologics 2014; 8: 91-105
58. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev 2014; 40(4): 523-32
59. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995; 333(21): 1380-5
60. Chan HS, Grogan TM, Haddad G, et al. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 1997; 89(22): 1706-15
61. Pakos EE, Ioannidis JP. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A metaanalysis. Cancer 2003; 98(3): 581-9
62. Serra M, Pasello M, Manara MC, et al. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol 2006; 29(6): 1459-68
63. Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003; 21(3): 536-42
64. Schwartz CL, Gorlick R, Teot L, et al. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 2007; 25(15): 2057-62
65. Serra M, Picci P, Ferrari S, Bacci G. Prognostic value of P-glycoprotein in high-grade osteosarcoma. J Clin Oncol 2007; 25(30): 4858-60; author reply 60-1
66. Gatti L, Beretta GL, Cossa G, et al. ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem 2009; 9(9): 1102-12
67. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007; 1775(2): 237-62
68. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010; 10(2): 147-56
69. Sero V, Tavanti E, Vella S, et al. Targeting polo-like kinase 1 by NMSP937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. Invest New Drugs 2014; 32(6): 1167-80
70. Tavanti E, Sero V, Vella S, et al. Preclinical validation of Aurora kinasestargeting drugs in osteosarcoma. Br J Cancer 2013; 109(10): 2607-18
71. Zhang X, Chen Q, Wang Y, et al. Effects of curcumin on ion channels and transporters. Front Physiol 2014; 5: 94
72. Barouch-Bentov R, Sauer K. Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs 2011; 20(2): 153-208
73. Hegedus C, Ozvegy-Laczka C, Szakacs G, Sarkadi B. Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: Substrates and/or inhibitors? Curr Cancer Drug Targets 2009; 9(3): 252-72
74. Brozik A, Hegedus C, Erdei Z, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: Substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 2011; 7(5): 623-42
75. Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group. Cancer 2009; 115(22): 5339-48
76. Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 2009; 9(8): 1035-49
77. Zhou Q, Deng Z, Zhu Y, et al. mTOR/ p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol 2010; 27(4): 1239-45
78. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrinmediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005; 65(6): 2406-11
79. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50(4): 799-805
80. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30(1): 78-84
81. Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013; 31(19): 2485-92
82. Moriceau G, Ory B, Mitrofan L, et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): Pivotal role of the prenylation process. Cancer Res 2010; 70(24): 10329-39
83. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007; 25(30): 4806-12
84. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134(3): 281-97
85. Abdeen A, Chou AJ, Healey JH, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009; 115(22): 5243-50
86. Fleuren ED, Versleijen-Jonkers YM, Roeffen MH, et al. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. Int J Cancer 2014; 135(12): 2770-82
87. Keir ST, Morton CL, Wu J, et al. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2012; 59(3): 586-8
88. Kasper B, Sleijfer S, Litiere S, et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol 2014; 25(3): 719-24
89. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27(19): 3126-32
90. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379(9829): 1879-86
91. Safwat A, Boysen A, Lucke A, Rossen P. Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients. Acta Oncol 2014; 53(10): 1451-4
92. Glade Bender JL, Lee A, Reid JM, et al. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: A children's oncology group phase I consortium report. J Clin Oncol 2013; 31(24): 3034-43
93. Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009; 8: 118
94. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study. Ann Oncol 2012; 23(2): 508-16
95. Pignochino Y, Dell'Aglio C, Basirico M, et al. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res 2013; 19(8): 2117-31
96. Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial. Lancet Oncol 2015; 16(1): 98-107
97. DeRenzo C, Gottschalk S. Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol 2014; 804: 323-40
98. Tarek N, Lee DA. Natural killer cells for osteosarcoma. Adv Exp Med Biol 2014; 804: 341-53
99. Suzuki M, Cheung NK. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets 2015; 19(3): 349-62
100. Poon VI, Roth M, Piperdi S, et al. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clin Sarcoma Res 2015; 5(1): 4
101. Roth M, Linkowski M, Tarim J, et al. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer 2014; 120(4): 548-54
102. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: A review of literature. Clin Exp Metastasis 2011; 28(5): 493-503
103. O'Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Expert Rev Anticancer Ther 2009; 9(4): 511-23
104. Yang Y, Niu X, Zhang Q, et al. The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine. Am J Med Sci 2012; 344(3): 199-205
105. Zhang L, Marrano P, Kumar S, et al. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Clin Cancer Res 2013; 19(21): 5972-83
106. Jain S, Vahdat LT. Eribulin mesylate. Clin Cancer Res 2011; 17(21): 6615-22
107. Kolb EA, Gorlick R, Reynolds CP, et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 2013; 60(8): 1325-32
108. Lucidarme N, Valteau-Couanet D, Oberlin O, et al. Phase II study of highdose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant 1998; 22(6): 535-40
109. Marec-Berard P, Segura-Ferlay C, Tabone MD, et al. High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group. Sarcoma 2014; 2014: 475067
110. Zak D, Styler MJ, Rosenbluth JZ, Brodsky I. Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma. Clin Adv Hematol Oncol 2005; 3(4): 297-9; discussion 300-2
111. Brennan RC, Furman W, Mao S, et al. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol 2014; 74(6): 1191-8
112. Karosas AO. Ewing's sarcoma. Am J Health Syst Pharm 2010; 67(19): 1599-605
113. Kratz F. DOXO-EMCH (INNO-206): The first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs 2007; 16(6): 855-66
114. Unger C, Haring B, Medinger M, et al. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res 2007; 13(16): 4858-66
115. Mita MM, Natale RB, Wolin EM, et al. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs 2015; 33(2): 341-8
116. Cheng L, Wang C, Jing J. Polo-like kinase 1 as a potential therapeutic target for osteosarcoma. Curr Pharm Des 2015; 21(10): 1347-50
117. Xu M, Xu CX, Bi WZ, et al. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone 2013; 57(1): 111-15
118. Jerjes W, Tan HB, Hopper C, Giannoudis PV. Spinal metastasis subjected to photodynamic therapy: An update. Hard Tissue 2012; 1(1): 8
119. O'Reilly KE, de Miera EV, Segura MF, et al. Hedgehog pathway blockade inhibits melanoma cell growth in vitro and in vivo. Pharmaceuticals (Basel) 2013; 6(11): 1429-50
120. Manara MC, Garofalo C, Ferrari S, et al. Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis. Curr Pharm Des 2013; 19(30): 5344-61
121. Wagner LM, Fouladi M, Ahmed A, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 2015; 62(3): 440-4
122. Zitvogel L, Kroemer G. Targeting PD-1/ PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1(8): 1223-5
123. Shen JK, Cote GM, Choy E, et al. Targeting programmed cell death ligand 1 in osteosarcoma: An auto-commentary on therapeutic potential. Oncoimmunology 2014; 3(8): e954467
124. Zheng W, Xiao H, Liu H, Zhou Y. Expression of programmed death 1 is correlated with progression of osteosarcoma. APMIS 2015; 123(2): 102-7
125. Lussier DM, O'Neill L, Nieves LM, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother 2015; 38(3): 96-106
126. Reimann E, Koks S, Ho X, et al. Whole exome sequencing of a single osteosarcoma case inverted question markintegrative analysis with whole transcriptome RNA-seq data. Hum Genomics 2014; 8(1): 20
127. Brown RE. Morphogenomics and morphoproteomics: A role for anatomic pathology in personalized medicine. Arch Pathol Lab Med 2009; 133(4): 568-79
128. Basu-Roy U, Basilico C, Mansukhani A. Perspectives on cancer stem cells in osteosarcoma. Cancer Lett 2013; 338(1): 158-67
129. Savage SA, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011; 2011: 548151
130. Yu W, Clyne M, Khoury MJ, Gwinn M. Phenopedia and Genopedia: diseasecentered and gene-centered views of the evolving knowledge of human genetic associations. Bioinformatics 2010; 26(1): 145-6